Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers Drewson, an anti-tumor biotherapeutic drug for the treatment of renal cancer, malignant melanoma, and cancerous thoracic and peritoneal effusion; and Xinde Lusheng for the treatment of kidney cancer, melanoma, lung cancer, gastric cancer, malignant lymphoma, breast cancer, ovarian tumor, bowel cancer, bladder cancer, head and neck tumor, leukemia and cancerous pleural effusion, etc. The company also provides Xin grain health, a recombinant human granulocyte colony stimulating factor injection; and Tourbo, a recombinant human erythropoietin injection for the treatment of anemia caused by renal insufficiency, including dialysis and non-dialysis patients. Jiangsu Sihuan Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Jiangyin, China.

Mr. Yang  Zhou

Secretary of the Board & Deputy GM

Name	Titel
Mr. Yang Zhou	Secretary of the Board & Deputy GM
Mr. Yu Guo	GM & Chairman
Ms. Haizhen Xu	Chief Financial Officer & Head of Accounting

Jiangsu Sihuan Bioengineering Co., Ltd

Jiangsu Sihuan Bioengineering Co., Ltd Management-Struktur

Informationen zum Management